The present state of the art in expression, production and characterization of monoclonal antibodies

Molecular Diversity

Volumn 20, Issue 1, 2016, Pages 255-270

  Gaughan, Christopher L ^a  

^a Zymera   (United States)

Author keywords

Biochemical engineering; CHO cell production; HPLC quality control monoclonal antibodies; Monoclonal antibodies; Monoclonal antibody platforms; Monoclonal antibody review; Scale up

Indexed keywords

EPITOPE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY TITER; BIOREACTOR; CELL SELECTION; CHO CELL LINE; CHROMATOGRAPHY; DISPOSABLE EQUIPMENT; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSFECTION; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGLOBULIN GENE; MASS SPECTROMETER; MASS SPECTROMETRY; MICROFILTRATION; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN A CHROMATOGRAPHY; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN TARGETING; QUALITY CONTROL; REVIEW; VIRUS INACTIVATION; ANIMAL; BIOSYNTHESIS; CRICETULUS; ECONOMICS; IMMUNOLOGY; LEGISLATION AND JURISPRUDENCE; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETULUS; HUMANS; PROTEIN ENGINEERING;

EID: 84954371457     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-015-9625-z     Document Type: Review

References (77)

1. Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS (2014) AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol 63:430–433. doi:10.1016/j.jacc.2013.09.048
2. Mizutani N, Nabe T, Yoshino S (2015) IgE/antigen-mediated enhancement of IgE production is a mechanism underlying the exacerbation of airway inflammation and remodelling in mice. Immunology 144:107–115. doi:10.1111/imm.12355
3. Gallagher-Colombo SM, Miller J, Cengel KA, Putt ME, Vinogradov SA, Busch TM (2015) Erlotinib pretreatment improves photodynamic therapy of non-small cell lung carcinoma xenografts via multiple mechanisms. Cancer Res. doi:10.1158/0008-5472.CAN-14-3304
4. Savic S, Diebold J, Zimmermann AK, Jochum W, Baschiera B, Grieshaber S, Tornillo L, Bisig B, Kerr K, Bubendorf L (2015) Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer. doi:10.1016/j.lungcan.2015.05.012
5. Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–352. doi:10.1038/nri2747
6. Lonberg N (2008) Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 20:450–459. doi:10.1016/j.coi.2008.06.004
7. Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7:9–14. doi:10.4161/19420862.2015.989042
8. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23:1073–1078. doi:10.1038/nbt0905-1073
9. Weiner LM (2006) Fully human therapeutic monoclonal antibodies. J Immunother 29:1–9
10. van Dijk MA, van de Winkel JGJ (2001) Human antibodies as next generation therapeutics. Curr Opin Chem Biol 5:368–374. doi:10.1016/S1367-5931(00)00216-7
11. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D (2007) Downstream processing of monoclonal antibodies-application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848:28–39. doi:10.1016/j.jchromb.2006.09.026
12. Czajkowsky DM, Hu J, Shao Z, Pleass RJ (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 4:1015–1028. doi:10.1002/emmm.201201379
13. Rita Costa A, Elisa Rodrigues M, Henriques M, Azeredo J, Oliveira R (2010) Guidelines to cell engineering for monoclonal antibody production. Eur J Pharm Biopharm 74:127–138. doi:10.1016/j.ejpb.2009.10.002
14. Banik GG, Todd PW, Kompala DS (1996) Foreign protein expression from S phase specific promoters in continuous cultures of recombinant CHO cells. Cytotechnology 22:179–184. doi:10.1007/BF00353937
15. Zhou M, Crawford Y, Ng D, Tung J, Pynn AF, Meier A, Yuk IH, Vijayasankaran N, Leach K, Joly J, Snedecor B, Shen A (2011) Decreasing lactate level and increasing antibody production in Chinese Hamster Ovary cells (CHO) by reducing the expression of lactate dehydrogenase and pyruvate dehydrogenase kinases. J Biotechnol 153:27–34. doi:10.1016/j.jbiotec.2011.03.003
16. Storey S (2010) Respiratory syncytial virus market. Nat Rev Drug Discov 9:15–16. doi:10.1038/nrd3075
17. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287
18. Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A (2010) Cell culture processes for monoclonal antibody production. MAbs 2:466–479
19. Zhu MM, Goyal A, Rank DL, Gupta SK, Vanden Boom T, Lee SS (2005) Effects of elevated pCO$$_2$$2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol Prog 21:70–77. doi:10.1021/bp049815s
20. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A (2012) Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28:147–175
21. Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Abanto SH, Urban L, Landucci G, Fischer R, Jiang X (2013) Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One 8:e58724. doi:10.1371/journal.pone.0058724
22. Malphettes L, Freyvert Y, Chang J, Liu P-Q, Chan E, Miller JC, Zhou Z, Nguyen T, Tsai C, Snowden AW, Collingwood TN, Gregory PD, Cost GJ (2010) Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng 106:774–783. doi:10.1002/bit.22751
23. Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5:505–517. doi:10.1038/nrmicro1681
24. Maloney DG (2005) Immunotherapy for non-Hodgkin’s lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 23:6421–6428. doi:10.1200/JCO.2005.06.004
25. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 107:18979–18984. doi:10.1073/pnas.1013387107
26. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774. doi:10.1038/nrd3229
27. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M, Mikulka W, Krueger P, Fairhurst J, Valenzuela DM, Papadopoulos N, Yancopoulos GD (2014) Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 111:5153–5158. doi:10.1073/pnas.1324022111
28. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12:433–455. doi:10.1146/annurev.iy.12.040194.002245
29. Clementi N, Mancini N, Solforosi L, Castelli M, Clementi M, Burioni R (2012) Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int J Mol Sci 13:8273–8292. doi:10.3390/ijms13078273
30. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4:372–384. doi:10.1038/nprot.2009.3
31. Kim J, Kim Y-G, Lee G (2012) CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 93:917–930. doi:10.1007/s00253-011-3758-5
32. Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398. doi:10.1038/nbt1026
33. Fan L, Kadura I, Krebs LE, Larson JL, Bowden DM, Frye CC (2013) Development of a highly-efficient CHO cell line generation system with engineered SV40E promoter. J Biotechnol 168:652–658. doi:10.1016/j.jbiotec.2013.08.021
34. Simonsen CC, Levinson AD (1983) Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 80:2495–2499
35. Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S (2013) Expression enhancement in trastuzumab therapeutic monoclonal antibody production using genomic amplification with methotrexate. Avicenna J Med Biotechnol 5:87–95
36. Cockett MI, Bebbington CR, Yarranton GT (1990) High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology (NY) 8:662–667
37. Kober L, Zehe C, Bode J (2013) Optimized signal peptides for the development of high expressing CHO cell lines. Biotechnol Bioeng 110:1164–1173. doi:10.1002/bit.24776
38. Xing Z, Kenty BM, Li ZJ, Lee SS (2009) Scale-up analysis for a CHO cell culture process in large-scale bioreactors. Biotechnol Bioeng 103:733–746. doi:10.1002/bit.22287
39. Varley J, Birch J (1999) Reactor design for large scale suspension animal cell culture. Cytotechnology 29:177–205. doi:10.1023/A:1008008021481
40. Pollock J, Ho SV, Farid SS (2013) Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. Biotechnol Bioeng 110:206–219. doi:10.1002/bit.24608
41. Lee JC, Chang HN, Oh DJ (2005) Recombinant antibody production by perfusion cultures of rCHO cells in a depth filter perfusion system. Biotechnol Prog 21:134–139. doi:10.1021/bp0497942
42. Tang YJ, Ohashi R, Hamel JF (2007) Perfusion culture of hybridoma cells for hyperproduction of IgG(2a) monoclonal antibody in a wave bioreactor-perfusion culture system. Biotechnol Prog 23:255–264. doi:10.1021/bp060299a
43. Crowley J, Wubben M, Martin JMC (2012) Process for cell culturing by continuous perfusion and alternating tangential flow. Google Patents
44. Diekmann S, Durr C, Herrmann A, Lindner I, Jozic D (2011) Single use bioreactors for the clinical production of monoclonal antibodies—a study to analyze the performance of a CHO cell line and the quality of the produced monoclonal antibody. BMC Proc 5(Suppl 8):P103. doi:10.1186/1753-6561-5-S8-P103
45. Singh V (1999) Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology 30:149–158. doi:10.1023/A:1008025016272
46. Smelko JP, Wiltberger KR, Hickman EF, Morris BJ, Blackburn TJ, Ryll T (2011) Performance of high intensity fed-batch mammalian cell cultures in disposable bioreactor systems. Biotechnol Prog 27:1358–1364. doi:10.1002/btpr.634
47. Gottschalk U (2009) Process scale purification of antibodies. Wiley, Hoboken
48. McNerney T, Thomas A, Senczuk A, Petty K, Zhao X, Piper R, Carvalho J, Hammond M, Sawant S, Bussiere J (2015) PDADMAC flocculation of Chinese hamster ovary cells: enabling a centrifuge-less harvest process for monoclonal antibodies. MAbs 7:413–428. doi:10.1080/19420862.2015.1007824
49. Keller K, Friedmann T, Boxman A (2001) The bioseparation needs for tomorrow. Trends Biotechnol 19:438–441
50. Liu HF, Ma J, Winter C, Bayer R (2010) Recovery and purification process development for monoclonal antibody production. mAbs 2:480–499. doi:10.4161/mabs.2.5.12645
51. Li NN, Fane AG, Ho WSW, Matsuura T (2011) Advanced membrane technology and applications. Wiley, Hoboken
52. Aunins JG, Wang DI (1989) Induced flocculation of animal cells in suspension culture. Biotechnol Bioeng 34:629–638. doi:10.1002/bit.260340507
53. Riske F, Schroeder J, Belliveau J, Kang X, Kutzko J, Menon MK (2007) The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery. J Biotechnol 128:813–823. doi:10.1016/j.jbiotec.2006.12.023
54. Hjelm H, Hjelm K, Sjoquist J (1972) Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett 28:73–76
55. Carter-Franklin JN, Victa C, McDonald P, Fahrner R (2007) Fragments of protein A eluted during protein A affinity chromatography. J Chromatogr A 1163:105–111. doi:10.1016/j.chroma.2007.06.012
56. Starovasnik MA, O’Connell MP, Fairbrother WJ, Kelley RF (1999) Antibody variable region binding by Staphylococcal protein A: thermodynamic analysis and location of the Fv binding site on E-domain. Protein Sci 8:1423–1431. doi:10.1110/ps.8.7.1423
57. Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M, Blank GS (2001) Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev 18:301–327
58. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y (2003) Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 82:321–329. doi:10.1002/bit.10574
59. Roberts PL (2014) Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps. Biotechnol Prog 30:1341–1347. doi:10.1002/btpr.1984
60. Roush DJ, Myrold A, Burnham MS, And JV, Hughes JV (2015) Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus. Biotechnol Prog 31:135–144. doi:10.1002/btpr.2020
61. J Immunother (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. 20:214–243
62. Burnouf T, Radosevich M (2003) Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 9:24–37. doi:10.1046/j.1365-2516.2003.00701.x
63. Sofer G (2003) Current issues in validation of chromatography. Dev Biol (Basel) 113:61–64
64. Kiefer P, Delmotte N, Vorholt JA (2011) Nanoscale ion-pair reversed-phase HPLC-MS for sensitive metabolome analysis. Anal Chem 83:850–855. doi:10.1021/ac102445r
65. He Y, Ning T, Xie T, Qiu Q, Zhang L, Sun Y, Jiang D, Fu K, Yin F, Zhang W, Shen L, Wang H, Li J, Lin Q, Sun Y, Li H, Zhu Y, Yang D (2011) Large-scale production of functional human serum albumin from transgenic rice seeds. Proc Natl Acad Sci 108:19078–19083. doi:10.1073/pnas.1109736108
66. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, Chen W, Skilton SJ, Mazzeo JR (2010) Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. mAbs 2:379–394. doi:10.4161/mabs.11986
67. Chen J, Tetrault J, Ley A (2008) Comparison of standard and new generation hydrophobic interaction chromatography resins in the monoclonal antibody purification process. J Chromatogr A 1177:272–281. doi:10.1016/j.chroma.2007.07.083
68. Kupiec TP (2004) Quality-control analytical methods: high-performance liquid chromatography. Int J Pharm Compd 8:223–227
69. Bongers J, Cummings JJ, Ebert MB, Federici MM, Gledhill L, Gulati D, Hilliard GM, Jones BH, Lee KR, Mozdzanowski J, Naimoli M, Burman S (2000) Validation of a peptide mapping method for a therapeutic monoclonal antibody: what could we possibly learn about a method we have run 100 times? J Pharm Biomed Anal 21:1099–1128
70. Bondarenko PV, Second TP, Zabrouskov V, Makarov AA, Zhang Z (2009) Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-Orbitrap mass spectrometer. J Am Soc Mass Spectrom 20:1415–1424. doi:10.1016/j.jasms.2009.03.020
71. Kelley B (2009) Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 1:443–452
72. Barnard G, Kull A, Sharkey N, Shaikh S, Rittenhour A, Burnina I, Jiang Y, Li F, Lynaugh H, Mitchell T, Nett J, Nylen A, Potgieter T, Prinz B, Rios S, Zha D, Sethuraman N, Stadheim T, Bobrowicz P (2010) High-throughput screening and selection of yeast cell lines expressing monoclonal antibodies. J Ind Microbiol Biotechnol 37:961–971. doi:10.1007/s10295-010-0746-1
73. Wang Y, Wei D, Yang H, Yang Y, Xing W, Li Y, Deng A (2009) Development of a highly sensitive and specific monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) for detection of Sudan I in food samples. Talanta 77:1783–1789. doi:10.1016/j.talanta.2008.10.016
74. Lee CJ, Seth G, Tsukuda J, Hamilton RW (2009) A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol Bioeng 102:1107–1118. doi:10.1002/bit.22126
75. Gerngross TU (2004) Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22:1409–1414. doi:10.1038/nbt1028
76. Nothaft H, Szymanski CM (2010) Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 8:765–778. doi:10.1038/nrmicro2383
77. Reichert JM, Dewitz MC (2006) Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 5:191–195